Abstract | PURPOSE: To study the additive effect of latanoprost 0.005% in patients who have uncontrolled intraocular pressure (IOP) using timolol 0.5% and dorzolamide 2%. METHODS: Fifty-two consecutive patients with open-angle glaucoma who were using timolol and dorzolamide and were considered to have IOP above their defined target pressure were included in this study. After a baseline diurnal tension curve (DTC) was performed, latanoprost once a day was added to the treatment, and a second DTC was performed 1 week later. RESULTS: Five patients (9.6%) were discontinued from treatment because of side effects. The remaining 47 patients showed a significant IOP reduction of 3.1 mm Hg (16%) from a baseline of 19.3 mm Hg (mean IOP registered during DTC; P < or = 0.0001). Seventeen patients (36.3%) showed a mean IOP reduction greater than 20%. CONCLUSIONS:
|
Authors | R Susanna Jr, M T Nicolela, E Oga |
Journal | Journal of glaucoma
(J Glaucoma)
Vol. 9
Issue 2
Pg. 183-6
(Apr 2000)
ISSN: 1057-0829 [Print] United States |
PMID | 10782630
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adrenergic beta-Antagonists
- Antihypertensive Agents
- Carbonic Anhydrase Inhibitors
- Prostaglandins F, Synthetic
- Sulfonamides
- Thiophenes
- Latanoprost
- Timolol
- dorzolamide
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Antihypertensive Agents
(therapeutic use)
- Carbonic Anhydrase Inhibitors
(therapeutic use)
- Circadian Rhythm
(physiology)
- Drug Synergism
- Drug Therapy, Combination
- Female
- Glaucoma, Open-Angle
(drug therapy, physiopathology)
- Humans
- Intraocular Pressure
(drug effects, physiology)
- Latanoprost
- Male
- Middle Aged
- Prostaglandins F, Synthetic
(therapeutic use)
- Sulfonamides
(therapeutic use)
- Thiophenes
(therapeutic use)
- Timolol
(therapeutic use)
- Treatment Outcome
|